Inhibitex

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting. We currently have two product candidates in clinical development and four product candidates in preclinical development. Our product candidates have been developed based upon our expertise in MSCRAMM® proteins, for which we own or have licensed numerous patents and patent applications. MSCRAMM® proteins are located on the surface of pathogenic organisms, such as bacteria and fungi, and play a prominent role in the process of infection. These proteins enable organisms to initiate and maintain an infection by adhering to specific sites on human tissue or implanted medical devices. Our antibody-based product candidates are designed to bind to specific MSCRAMM® proteins, thereby reducing the incidence and severity of infections.
Our lead product candidate, Veronate®, is being developed for the prevention of hospital-associated infections in premature, very low birth weight (VLBW) infants. We have completed the enrollment phase of a 2,000 patent pivotal Phase III trial of Veronate®, and we anticipate data from this trial to be available in the second quarter of 2006. Veronate® has been granted both Fast Track and Orphan Drug status by the FDA and has been designated an orphan medicinal product by the EMEA in Europe. Our second product candidate, Aurexis®, is being evaluated in clinical trials as a first-line therapy, in combination with standard of care antibiotics, to treat serious Staphylococcus aureus (S. aureus) bloodstream infections in hospitalized patients.

Contact Details: 9005 Westside Parkway Alpharetta Georgia 30004 United States of America Tel: 678.746.1100 Fax: Email: WWW: www.inhibitex.com/

Loading...

Recent Publications by Inhibitex:
Unique anthranilic acid chemistry facilitates profiling and characterization of Ser/Thr-linked sugar chains following hydrazinolysis. A novel method for the analysis of Ser/Thr-linked sugar chains was made...	8th March, 2008	Analytical Biochemistry, Research and Development, Inhibitex, Alpharetta,	Anal Biochem. 2008 Feb 1;373(1):104-11. Epub 2007 Sep 25. DOI Direct Link
Automated sample preparation facilitated by PhyNexus MEA purification system for oligosaccharide mapping of glycoproteins. A reproducible high-throughput sample cleanup method for fluorescent...	6th December, 2007	Analytical Chemistry, Inhibitex, Alpharetta, GA 30004, USA.	Anal Biochem. 2007 Oct 15;369(2):202-9. Epub 2007 Jul 25. DOI Direct Link
Monoclonal antibodies recognizing the Enterococcus faecalis collagen-binding MSCRAMM Ace: conditional expression and binding analysis. Enterococci are opportunistic pathogens known to cause numerous clinical...	26th September, 2007	Inhibitex, Inc., 9005 Westside Parkway, Alpharetta, GA 30004, USA.	Microb Pathog. 2007 Aug-Sep;43(2-3):55-66. Epub 2007 Apr 19. DOI Direct Link
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG. Staphylococcus epidermidis is an important opportunistic human pathogen...	22nd March, 2007	Inhibitex, Inc., Alpharetta, Georgia 30004, USA.	Hybridoma (Larchmt). 2007 Feb;26(1):28-34. DOI Direct Link
Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. Nosocomial or hospital-acquired infections are associated with prolonged...	28th April, 2006	Analytical Biochemistry, Inhibitex Inc., Alpharetta, GA 30004, USA.	Anal Biochem. 2006 Mar 1;350(1):1-23. Epub 2005 Oct 17. DOI Direct Link
→View more Inhibitex research publications.

BioNews Results for Inhibitex:
Inhibitex Reports Second Quarter 2008 Financial Results and Highlights	DiGiTAL50:  Aug 13 2008 11:57AM Matching: inhibitex
Inhibitex Reports Second Quarter 2008 Financial Results and Highlights	Genetic Engineering News:  Aug 12 2008 10:44AM Matching: inhibitex
Inhibitex Reports Initiation of Multiple Ascending Dose Trial of FV-100 for Shingles	PipelineReview:  Aug 12 2008 9:40PM Matching: inhibitex
Inhibitex initiates Phase I multiple ascending dose shingles trial	Pharmaceutical Business Review:  Aug 8 2008 1:31AM Matching: inhibitex
Inhibitex Reports Initiation of Multiple Ascending Dose Trial of FV-100 for Shingles	Pharma Live:  Aug 7 2008 6:36PM Matching: inhibitex
Promote your company here: BioNewsCast - Press Release Distribution	→View more Inhibitex news.

Inhibitex Patents:
US Patent No.	Title
7381793	Extracellular matrix-binding proteins from Staphylococcus aureus
6692739	Staphylococcal immunotherapeutics via donor selection and donor stimulation
6703025	Multicomponent vaccines
6841154	Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
6979446	Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
→View more Inhibitex patents.

Inhibitex (INHX) Financial information Links from Barchart
INHX Quote from from Barchart.com
INHX Chart from from Barchart.com
INHX Profile from from Barchart.com
INHX Opinion from from Barchart.com
→View more Inhibitex finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 228 times since April 2007, the link to the organisation's website has been followed 38 times

Recent Search Terms used to find this page: Inhibitex | Inhibitex Alpharetta | enterococcus inhibitex | aurexis cross-reactive | .

Search for more companies in Alpharetta

Search for more companies in Georgia

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Inhibitex